209222-81-1

Basic information

• Product Name: 2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine
• Synonyms: 2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine
• CAS NO: 209222-81-1
• Molecular Weight: 359.469
• Mol File: 209222-81-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine(209222-81-1)
• EPA Substance Registry System: 2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine(209222-81-1)

Safety Data

• Hazardous Substances Data: 209222-81-1(Hazardous Substances Data)

Downstream Products

• 209222-91-3 1-(pyrrolidin-1-ylcarbonylmethyl)-2-oxo-3-(N-tert-butoxycarbonyl)amino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 209222-88-8 1-(2-thenoylmethyl)-2-oxo-3-(N-tert-butoxycarbonyl)amino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 209219-27-2 3-[3-[1-(N-methyl-N-phenylcarbamoylmethyl)-2-oxo-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-3-yl]ureido]benzoic acid 
• 209222-89-9 1-(2-thenoylmethyl)-2-oxo-3-amino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 209223-03-0 1-(N-tert-butyl)carbamoylmethyl-2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 

Relevant articles and documents

1,5-benzodiazepine derivatives

This invention relates to 1,5-benzodiazepine derivatives, which are each represented by the following formula (1): wherein R1represents a lower alkyl group, R2and R3may be the same or different and represent a hydrogen atom or a lower alkyl group, R4represents a cyclohexyl group or phenyl group, and n stands for an integer of from 1 to 3, and also to medicines containing the same. These compounds are useful as curatives or preventives for diseases in which a gastrin receptor and/or a CCK-B receptor takes part.